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Abstract:
Background:
Sulindac belongs to the chemically diverse family of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) that effectively prevent
adenomatous colorectal polyps and colon cancer, especially in patients with familial adenomatous polyposis. Sulindac sulfide amide
(SSA),  an  amide  analog  of  sulindac  sulfide,  shows  insignificant  COX-related  activity  and  toxicity  while  enhancing  anticancer
activity in vitro and demonstrating in vivo xenograft activity.
Objective:
Develop structure-activity relationships in the sulindac amine series and identify analogs with promising anticancer activities.
Method:
A series of sulindac amine analogs were designed and synthesized and then further modified in a “libraries from libraries” approach
to produce amide, sulfonamide and N,N-disubstituted sulindac amine sub-libraries. All analogs were screened against three cancer
cell lines (prostate, colon and breast).
Results:
Several active compounds were identified viain vitro cancer cell line screening with the most potent compound (26) in the nanomolar
range.
Conclusion:
Compound 26 and analogs showing the most potent inhibitory activity may be considered for further design and optimization efforts
as anticancer hit scaffolds.
Keywords: NSAIDs, Sulindac, COX-independent, Reverse amide, Sulfonamide, Cancer, Anticancer.
1. INTRODUCTION
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are a structurally diverse group of agents that are used to treat
chronic  inflammatory  diseases  such  as  rheumatoid  arthritis  as  well  as  acute  symptoms  of  inflammation.  Certain
NSAIDs  are  also  effective  antipyretics  and  analgesics.  The   pharmacological   basis  for   their   anti-inflammatory
 activity involves the inhibition of COX isozymes (COX-1 and COX-2) and  blockage of  arachidonic  acid  conversion
* Address correspondence to this authors at the Division of Hematology and Oncology, The University of Alabama at Birmingham, Birmingham,
Alabama 35294, USA, Tel: +1-(205) 934-8276; Fax: +1-(205) 934-2543; E-mail: rcr12lkt@uab.edu
2   The Open Medicinal Chemistry Journal, 2018, Volume 12 Mathew et al.
to prostaglandin H2, a precursor for the synthesis of prostaglandins, prostacyclins, and thromboxanes [1]. COX-1 is a
constitutively  expressed  enzyme responsible  for  the  regulation  of  prostaglandin  biosynthesis  in  normal  tissues  and
serves an important role in gastric cytoprotection, renal homeostasis, and platelet activation, while COX-2 is selectively
and acutely expressed by inflammatory cells  and certain cancers.  Evidence from experimental  and epidemiological
studies, and clinical trials suggests that the regular use of NSAIDs can reduce the incidence and mortality of colorectal
cancer by as much as 50% [2, 3]. The most compelling evidence for the role of NSAIDs in the prevention of colorectal
tumors comes from clinical studies in patients with familial adenomatous polyposis (FAP) [4, 5]. However, chronic
COX inhibition is associated with gastrointestinal, renal, and cardiovascular side effects, limiting the use of NSAIDs
and COX-2 selective inhibitors for cancer chemoprevention [6 - 10]. NSAIDs are believed to display their anticancer
effects  through  inhibition  of  COX-2,  as  this  isozyme  is  thought  to  play  a  role  in  carcinogenesis  and  is  often  over
expressed in human premalignant and malignant tissues [11 - 13]. Other published work suggests that NSAIDs may
have COX/COX-2 independent effects. For example, cells lacking COX-1 and/or COX-2 show comparable sensitivity
to NSAID-induced apoptosis, and, furthermore, NSAIDs that do not significantly inhibit COX-2 also induce apoptosis
and  inhibit  carcinogenesis  [14  -  17].  Accumulating  evidence  for  COX-independent  mechanisms underlying  certain
anticancer activities of the NSAIDs have been recently reviewed [18, 19]. A number of chemically modified NSAIDs
has been also developed aiming to improve the efficacy and safety of conventional NSAIDs [20].
Sulindac  belongs  to  the  chemically  diverse  group  of  Non-Steroidal  Anti-Inflammatory  Drugs  (NSAIDs)  that
effectively prevent adenomatous colorectal polyps and colon cancer, especially in patients with familial adenomatous
polyposis [21 - 25]. Exisulind (sulindac sulfone), an oxidative metabolite of sulindac that lacks cyclooxygenase (COX)
inhibitory activity, has also been shown to decrease polyp size and number in familial adenomatous polyposis patients,
inhibit chemical carcinogenesis in rodents, and inhibit growth and induce apoptosis in a variety of human cancer cell
lines [26 - 29]. As reported previously, Sulindac Sulfide Amide (SSA, Fig. (1), obtained from sulindac sulfide (1) and
N,N-dimethylethylenediamine replacing the carboxylate moiety in sulindac, shows severely attenuated COX inhibition
while demonstrating excellent anticancer activity in vitro compared to the parent compound sulindac sulfide as well as
having in  vivo  murine  xenograft  activity  [30].  Hence,  we have synthesized additional  sulindac libraries  in  order  to
further probe the anticancer activity of this promising class of NSAIDs.
Clearly, numerous alternative targets other than the COX isozymes have specifically been implicated in the activity
of sulindac including platelet activating factor (PAF), retinoid receptors (RXRα and RXRα-dependent AKT signaling),
cyclic-GMP phosphodiesterase, peroxisome proliferator-activated receptor (PPARγ), 5-lipoxygenase, Smad2/3, Wnt/ß-
catenin, NF-κB, Ras/Raf/P53 pathways, and specificity protein transcription factors (Sp) among others [reviewed in 18,
31]. In fact, at a recent meeting to discuss alternative targets for the NSAIDs, it was stated “. . . at the very least, the
studies finding non-COX-2-related effects of NSAIDS are identifying potential new targets for drugs that can be used to
prevent or treat cancer” [32]
Hence, it is our hypothesis that diversity libraries built around the classical, “privileged” NSAID scaffolds will show
numerous and interesting biological activities that can be used to study the chemical biology of this class with a goal of
exploring interesting potential targets beyond the cyclooxygenases for new drug discovery. The fact that both Exisuland
and our lead SSA showed severely attenuated COX inhibition was a strong basis for preparing similar analogs that
showed  abrogated  COX  inhibition  allowing  us  to  potentially  better  explore  “off  target”  activities  of  the  sulindac
scaffold.  The  lack  of  COX-2  inhibition  of  SSA  supports  our  modelling-based  hypothesis  that  replacement  of  the
carboxylate moiety of sulindac with basic substituents may attenuate or abolish COX-2 binding of analogs derived from
sulindac  (described  below).  Further  substitution  vectors  for  designing  out  COX-2  activity  are  predicted  in  the
benzylidene moiety  of  sulindac,  particularly  in  3-,  4-,  5-positions  of  benzene.  We designed a  variety  of  series  that
explore these opportunities to remove COX inhibition while potentially expanding into non-COX active anticancer
space. In the present manuscript, we describe the synthesis and anticancer activity of a series of sulindac ethane amines
and sulindac methane amines (7-13, 16-17) as shown in Fig. (1). These compounds were further modified to amide (14,
18-33), sulfonamide (34-47) and N,N-disubstituted sulindac amine (48-61) libraries in order to further probe anticancer
activity of this class (Fig. 1).
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Fig. (1). Overview of structural modifications related to SSA.
2.. Materials and Methods
2.1. Chemistry
The general synthetic route used to prepare the target compounds 7-12 is outlined in Scheme (1). Synthesis started
with the conversion of sulindac, sulindac sulfide or sulindac sulfone (1-3) to the methyl esters, which were converted to
the corresponding aldehydes (4-6) by treating with DIBALH. Finally, reductive amination of the aldehydes with various
substituted amines afforded compounds 7-12 in moderate to good yields [33].
Scheme (1). Synthetic pathways to analogs 7-12. Reagents and conditions: (a) MeOH, SOCl2 (b) DIBAL-H, Toluene (c) NaBH4,
MeOH, rt (d) Na(OAc)3BH, 1,2-DCE, rt.
Sulindac sulfide ethane amine 13 was prepared from sulindac sulfide (1) following the four-step sequence shown in
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Scheme (2). The sequence involved the reduction of the acid to the corresponding alcohol, which was then converted to
an  iodide  by  treating  with  tetrabutylammonium  iodide,  pyridine  and  trifluoromethanesulfonic  anhydride  [34].  The
iodide was then converted to the corresponding azide using sodium azide followed by a Staudinger type reduction [35]
to  give  sulindac  sulfide  ethane  amine  13.  Amine  13  was  further  transformed  to  amide  14  using  standard  peptide
coupling conditions.
Scheme (2). Synthetic pathways to analogs 13-14. Reagents and conditions: (a) BH3/THF, 0 
oC-rt (b) TBAI, Pyridine, CH2Cl2, Tf2O,
-78 oC-rt (c) NaN3, MeCN, reflux (d) PPh3, rt (e) 2-Furoic acid, HBTU, Et3N, MeCN, rt.
Scheme  (3).  Synthetic  pathways  to  analogs  14-59.  Reagents  and  conditions:  (a)  Oxalyl  chloride,  DMF,  CH2Cl2,  rt  (b)
trimethylsilylazide,  CCl4,  rt-50  
oC  (c)  AcOH/HCl  (d)  RCO2H,  HATU,  DIEA,  MeCN  (e)  RSO2Cl,  NMI,  Pyridine  (f)  RCHO,
Na(OAc)3BH, 1,2-DCE, rt
Methane amine analogs (16-17) of different sulindac derivatives were synthesized from their corresponding acids
(1, 15) by treating with oxalyl chloride followed by trimethylsilyl azide and acetic acid [34]. These amines were further
modified in three ways: 1) conversion to amides by reacting with various acids (18-33); 2) conversion to sulfonamides
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by reacting with sulfonyl chlorides and pyridine (34-47) and; 3) reductive amination of 16 or 17 with various aldehydes
and Na(OAc)3BH to afford bis amino substituted sulindac methane amines (48-61) Scheme (3) [33].
3. RESULTS AND DISCUSSION
3.1. Screening Results
Using quantitative high-throughput screens (qHTS) all synthesized compounds were screened against three cancer
cell lines: HT29 colorectal carcinoma, PC3 prostate and MDA-MB-231 breast cancer cell lines according to reported
methods – see Supplementary Material, Appendix A. Screening results are summarized in (Tables 1-6).
Table 1. Screening data for compounds 7-12.
Cmpd R & R1
CC50 (µM)
HT29 PC3 MDA-MB-231
SSA 0.65±0.03 3.12±0.15 2.67±0.08
7 R1 = SCH3, R = benzyl 21.83±2.29 >50.00 46.51±1.92
8 R1 = SCH3, R = furan-2-ylmethyl 4.27±0.33 9.94±0.77 7.77±0.54
9 R1 = SCH3, R = 1-pipyridinylethyl 1.81±0.06 4.78±0.20 3.73±0.21
10 R1 = SCH3, R = CH2CH2N(CH3)2 1.97±0.18 4.38±0.25 3.42±1.50
11 R1 = SOCH3, R = benzyl 15.14±1.42 41.46±5.00 48.57±7.85
12 R1 = SO2CH3, R = benzyl 3.39±0.28 7.02±0.48 4.52±0.77
Table (1) lists the anticancer activity of compounds 7-12 in colon, prostate and breast cancer cell lines. Compound
10,  the  amine  analog  of  SSA,  was  found  to  be  active,  but  slightly  less  potent  than  SSA.  Compound  9  with  a  4-
methylthiobenzylidene ring at the C-1 position and 1-pipyridinylethylaminoethyl group at the C-3 position had activity
very similar  to 10.  Among benzylaminoethyl  analogs of  sulindac sulfide,  sulfoxide and sulfone (7,  11  and 12),  the
sulindac sulfone analog 12 displayed significant anticancer activity. The furan-2-ylmethylaminoethyl analog of sulindac
sulfide (8) was active against HT29, PC3 and MDA-MB-231 cells, but was slightly less potent than SSA.
Table 2. Screening data for compounds 13-14.
Cmpd
CC50 (µM)
HT29 PC3 MDA-MB-231
13 4.05±0.16 7.46±0.46 7.20±0.29
14 9.24±1.18 8.92±0.83 16.78±3.20
Sulindac sulfide ethane amine 13 Table (2) was prepared to study the role of substituents at the amino ethane group.
Compound 13 was modestly less active than its 1-pipyridinylethyl and N,N-dimethylaminoethyl counterparts 9 and 10,
but more active than its benzyl derivative 7 (Table 1). No significant differences were observed in the case of 13 and its
furan-2-ylmethyl analog 8. These results demonstrate that appropriate amino ethane analogs show significant activity
relative to sulindac and its metabolites as well as other analogs. Conversion of 13 to its reverse amide analog 14 slightly
reduced potency by two fold, and the reverse amide was also modestly less potent than reduced analog 8.
Table 3. Screening data for compounds 16-17.
Cmpd R1, R2 & R3
CC50 (µM)
HT29 PC3 MDA-MB-231
16 R1 & R3 = H, R2 = SCH3 15.99±6.08 33.60±6.59 19.33±2.12
17 R1, R2 & R3 = OCH3 14.64±2.42 29.73±4.49 15.35±4.44
Two analogs 16 and 17 Table (3) were prepared to study the effect of substituting an amino methyl linker for the
amino ethyl linker in 13. Both analogs were less active than 13 against all three cancer cell lines, while their potencies
were comparable.
Compounds 16 and 17 were further modified to reverse amide analogs 18-33 Table (4), sulfonamide derivatives
34-47 Table (5) and disubstituted amino derivatives 48-61 Table (6) to explore the role of different functional groups in
anticancer  activity.  Compounds  18-33,  which  contain  an  amide  moiety  at  the  C-3  position,  displayed  significant
anticancer  activity  in  all  the  three  cell  lines  except  their  furan-2-yl  analogs  19  and  27.  Importantly,  3,4,5-
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trimethoxybenzylidene-3-indenylmethyl-2-phenylacetamide (26) was the most effective and potent inhibitor of cancer
cell growth among all the compounds tested, with CC50 of <98.0 nM in colon and breast cancer cells and 520.0 nM in
prostate cancer cells. Among all the sulfonamide derivatives 34-47, 4-thiomethylbenzylidine analogs 34-40 were more
active  than  their  3,4,5-trimethoxybenzylidine  analogs  41-47.  Conversion  of  methaneamine  linker  to  a  series  of
disubstituted  methaneamine  compounds  reduced  potency,  except  for  the  pyridyl  analogs  49  and  56.
Table 4. Screening data for compounds 18-33.
Cmpd R, R1, R2 & R3
CC50 (µM)
HT29 PC3 MDA-MB-231
18 R1 & R3 = H, R2 = SCH3, R = benzyl 3.56±1.25 18.86±9.71 4.06±1.97
19 R1 & R3 = H, R2 = SCH3, R = furan-2-yl 33.25±3.43 39.79±6.81 41.16±7.60
20
R1 & R3 = H, R2 = SCH3, R = >
3.64±0.21 4.81±0.99 7.24±0.56
21 R1 & R3 = H, R2 = SCH3, R = aminomethyl 5.49±0.21 7.27±0.31 7.30±0.62
22
R1 & R3 = H, R2 = SCH3, R = 
5.98±0.24 6.03±0.41 7.43±0.87
23 R1 & R3 = H, R2 = SCH3, R = 
4.39±0.29 6.21±0.49 6.70±0.71
24
R1 & R3 = H, R2 = SCH3, R = 
4.23±0.16 5.16±0.50 6.81±0.63
25
R1 & R3 = H, R2 = SCH3, R = 
3.15±0.17 6.66±0.42 4.35±0.19
26 R1, R2 & R3 = OCH3, R = benzyl <0.098±0 0.52±0 <0.098±0.04
27 R1, R2 & R3 = OCH3, R = furan-2-yl >50.00 >50.00 >50.00
28 R1, R2 & R3 = OCH3, R = methyl 6.44±1.40 23.26±2.61 5.77±1.55
29 R1, R2 & R3 = OCH3, R = aminomethyl 8.51±1.70 17.92±2.08 9.92±2.13
30
R1, R2 & R3 = OCH3, R = 
11.05±1.35 26.53±6.01 11.94±2.27
31
R1, R2 & R3 = OCH3, R = 
5.21±0.39 11.95±1.47 8.87±1.38
32
R1, R2 & R3 = OCH3, R = 
4.87±0.11 8.11±0.41 7.30±0.73
33
R1, R2 & R3 = OCH3, R = 
5.67±1.67 11.94±1.56 8.20±0.99
Table 5. Screening data for compounds 34-47.
Cmpd R, R1, R2 & R3
CC50 (µM)
HT29 PC3 MDA-MB-231
34 R1 & R3 = H, R2 = SCH3, R = methyl 7.43±0.48 20.18±3.20 9.06±2.26
35 R1 & R3 = H, R2 = SCH3, R = ethyl 8.33±1.64 22.59±3.25 11.87±2.61
36 R1 & R3 = H, R2 = SCH3, R = phenyl 9.94±0.83 39.58±14.8 17.72±2.10
37 R1 & R3 = H, R2 = SCH3, R = p-tolyl 8.08±0.60 >50.00 20.53±5.18
38 R1 & R3 = H, R2 = SCH3, R = 1-naphthyl 17.03±3.73 >50.00 38.90±10.32
39 R1 & R3 = H, R2 = SCH3, R = 2-naphthyl 25.64±5.91 >50.00 12.92±2.39
40 R1 & R3 = H, R2 = SCH3, R = 5-N,N-Dimethylamino-1-naphthyl 38.41±10.12 >50.00 >50.00
41 R1, R2 & R3 = OCH3, R = methyl 20.02±4.86 18.85±2.47 12.91±1.79
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Cmpd R, R1, R2 & R3
CC50 (µM)
HT29 PC3 MDA-MB-231
42 R1, R2 & R3 = OCH3, R = ethyl 15.56±5.56 15.13±1.84 6.58±1.39
43 R1, R2 & R3 = OCH3, R = phenyl 43.77±23.02 40.88±16.80 16.28±3.96
44 R1, R2 & R3 = OCH3, R = p-tolyl >50.00 >50.00 44.48±25.65
45 R1, R2 & R3 = OCH3, R = 1-naphthyl >50.00 >50.00 >50.00
46 R1, R2 & R3 = OCH3, R = 2-naphthyl >50.00 >50.00 >50.00
47 R1, R2 & R3 = OCH3, R = 5-N,N-Dimethylamino-1-naphthyl >50.00 >50.00 >50.00
3.2. Cytotoxicity Evaluations and Screening Against a Panel of Additional Cancer Cell Lines
Most analogs in the presented series are lipophilic while also containing a positively charged amine. Lipophilic
basic amines can accumulate in cell membranes if their lipophilic atom groups form favorable non-polar contacts with
lipid chains while their charged amine is interacting with fatty acid head groups. Such association with lipids can lead to
cytotoxicity through membrane destabilization. Therefore, we evaluated a number of representative compounds against
BJ cells, a normal human foreskin fibroblast cell line, where cytotoxicity was determined at 10 µM drug concentration,
as  described  previously  [36].  Results  of  cytotoxicity  evaluations  for  selected  compounds  are  shown  in  Table  S-1
(Supplementary materials: Appendix A). BJ cytotoxicity evaluation suggests that these compounds are not cytotoxic. In
particular, compound 26 possessing the highest potency against all three cancer cell lines shows EC50 > 22.73 µM in the
BJ  cytotoxicity  assay.  Further,  Table  S1  includes  screening  results  against  a  panel  of  additional  cancer  cell  lines
performed at St. Jude Children’s Research Hospital for selected compounds (as described in Supplementary materials:
Appendix A). Compound 26 stands out as having inhibitory activity against five acute lymphoblastic leukemia cell lines
used  on  this  panel  (Table  S1),  and  thus  this  compound  may  be  considered  a  viable  lead  for  further  development.
Compounds 20, 23, 24, 26, 32 and 56 were active against multiple leukemia cell lines showing a wide range of efficacy
while also inhibiting the three (HT29, PC3, MDA-MB-231) cancer cell lines with CC50 < 10 µM potency.
Table 6. Screening data for compounds 48-61.
Cmpd R, R1, R2 & R3
CC50 (µM)
HT29 PC3 MDA-MB-231
48 R1 & R3 = H, R2 = SCH3, R = phenyl >50.00 >50.00 >50.00
49 R1 & R3 = H, R2 = SCH3, R = 4-pyridyl 10.76±1.84 12.73±1.44 9.50±2.14
50 R1 & R3 = H, R2 = SCH3, R = 4-Fluorophenyl >50.00 >50.00 >50.00
51 R1 & R3 = H, R2 = SCH3, R = 4-N,N-Dimethylaminophenyl >50.00 >50.00 >50.00
52 R1 & R3 = H, R2 = SCH3, R = 2-naphthyl >50.00 >50.00 >50.00
53 R1 & R3 = H, R2 = SCH3, R = benzyl >50.00 >50.00 >50.00
54 R1 & R3 = H, R2 = SCH3, R = furan-2-yl >50.00 >50.00 48.76±20.34
55 R1, R2 & R3 = OCH3, R = phenyl >50.00 >50.00 >50.00
56 R1, R2 & R3 = OCH3, R = 4-pyridyl 9.83±1.54 9.09±0.87 8.21±0.90
57 R1, R2 & R3 = OCH3, R = 4-fluorophenyl >50.00 >50.00 >50.00
58 R1, R2 & R3 = OCH3, R = 2-naphthyl >50.00 >50.00 >50.00
59 R1, R2 & R3 = OCH3, R = 4-methoxyphenyl >50.00 >50.00 >50.00
60 R1, R2 & R3 = OCH3, R = benzyl >50.00 >50.00 >50.00
61 R1, R2 & R3 = OCH3, R = furan-2-yl >50.00 >50.00 >50.00
3.3. Sulindac Amine Derivatives Versus Sulindac Modelled into COX-2
The binding mode of sulindac, a known COX-2 inhibitor was predicted based on the X-ray structure of COX-2
(PDB code 4COX) using Induced Fit docking as implemented in Schrödinger software Fig. (2). The carboxylate group
of sulindac forms a hydrogen bond with Y355 and highly favorable, salt bridging/hydrogen bonding interactions with
R120, while the conformation of the R120 side chain is restrained by a salt bridge to E524. These favorable contacts are
also  present  in  the  X-ray  structure  of  COX-2  (PDB code  4COX)  through  the  carboxylate  group  of  co-crystallized
indomethacin.  Docking  places  the  carboxylate  of  sulindac  in  overlapping  position  with  that  of  indomethacin  co-
crystallized in COX-2.
The carboxylate functionality of sulindac was replaced by various basic amine containing groups in the presented
amine derivative series, none of which are suitable for forming favorable polar interactions with Arg120. In addition to
(Table 5) contd.....
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the loss of salt bridging and hydrogen bonding interactions, basic amine groups close to the guanidinium moiety of
R120 would not be favorable. This is illustrated by superimposing a representative analog (10) onto sulindac in Fig. (2).
Compound 10 could not be docked favorably into COX-2, even while treating residues in the binding site region as
flexible.  Compound  10  has  a  very  similar  structure  to  SSA (sulindac  sulfide  amide).  The  difference  between  their
structures is that an amide group in SSA is replaced by a more basic methylene-amine group in compound 10 Fig. (1),
Scheme (1). Superposition of compound 10 onto sulindac places this group in approximately overlapping space with the
carboxylate of sulindac and near R120 Fig. (2). Interestingly, SSA inhibits human colon tumor cell lines while showing
no activity against COX-1 and COX-2 [30]. The lack of COX-2 activity of SSA supports our analogous, model based
prediction that compound 10 and its analogs containing basic amine substituents are unlikely to inhibit COX-2. Similar
reasoning  was  incorporated  in  SSA  analog  designs  previously  as  in  our  approach  to  design  out  COX-2  inhibitory
activity through replacement of the carboxylate of sulindac with a variety of amine containing substituents [15].
Fig. (2). Sulindac (orange carbons) docked into the COX-2 active site and the superimposed compound 10 (green colored carbons).
The docked pose of  sulindac suggests  further  vectors  to  explore  for  the  design of  new analogs  inactive  against
COX-2. In the docked pose of sulindac the benzylidene moiety is accommodated in a deep-lying pocket, surrounded by
largely non-polar residues as shown in Fig. (2): F381, L384, W387, F518, M522, V523, L352, as well as (residues not
shown for clarity) G526, A527, Y385. Tight packing of residues around the benzene ring especially in the region of C3,
C5 include the side chains of Y385, W387 and backbone atoms of M522, V523, which restrict pocket volume available
for 3-, 5- substituents. The 4-methylsulfinyl substituent is fitted tightly in a small cavity forming a hydrogen bonding
interaction with W387. Limited cavity space in this region suggests that 3-, 4-, 5-substitutions of the benzene ring may
lead to steric hindrance, interfering with the binding of sulindac analogs to COX-2. Therefore benzene substitutions
have been also explored in the presented analog series.
3.4. Computed Physicochemical Properties
Favorable  permeability  and metabolic  stability  are  key properties  relevant  to  oral  bioavailability  that  should be
considered early on during lead optimization. In order to assess physicochemical properties of our most potent series
(7-33)  we correlated  logD and molecular  weight  (MW) of  the  compounds  and selected  the  analogs  that  map to  an
optimal ‘Golden Triangle’ region as shown in Fig. (3), as proposed based on results of previous studies [37, 38]. For
example, Johnson and co-workers [37] used in vitro permeability data available in Caco-2 cells for 16,227 compounds
and in vitro metabolic clearance data derived from human liver microsome (HLM) stability for 47,018 compounds for a
correlation analysis with computed physicochemical  properties [37].  Among physicochemical  properties,  logD was
found  to  positively  correlate  with  permeability,  except  at  high  logD  values.  Metabolic  clearance  was  negatively
correlated with logD and molecular weight (MW). Permeability and HLM stability data have been combined in order to
deduce  the  optimal  ranges  for  logD and MW which describe  compounds  that  possess  both,  good permeability  and
metabolic stability properties. The optimal ranges map approximately to a triangular area (‘Golden Triangle’) in a plot
of MW versus  logD (with a baseline at MW 200 between logD -2 to 5 and apex at MW 450 between logD 1 – 2).
Similar  results  have  been  obtained  based  on  the  logD  and  Caco-2  permeability  data  analysis  of  9,571  structurally
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diverse compounds [38]. Therefore, we chose to correlate MW and logD for the compounds in our series and identify
those that map to or near the optimal ranges. Fig. (3) illustrates several active analogs that map to the “goldilocks area”
(13, 16, 17) or near the borderline of this optimal zone (21, 29, 30), which may be associated with desirable in vivo
permeability and metabolic clearance properties based on the mentioned published findings. Table S2 (Supplementary
Materials: Appendix A) lists computed physicochemical properties for the series 7-33.
Fig. (3). Sulindac (orange carbons) docked into the COX-2 active site and the superimposed compound 10 (green colored carbons).
CONCLUSION
In summary, we prepared a series of sulindac analogs with significant anticancer activity in HT29, PC3 and MDA-
MB-231 cells, exploring synthetic vectors suggested by our modelling results. A number of new compounds have been
identified that maintain potent inhibitory activity against the three cancer cell lines and additionally show improved
computed physicochemical properties. For example, compounds 13, 16, 17, 21, 29, 30 possess logD and MW values
that map to the Golden Triangle region of property space that has been associated with better in vivo permeability and
improved metabolic stability properties. Compound 26 shows significant anticancer activity in all three cell lines and
was active against five acute lymphoblastic leukemia cell lines as well. In comparison with our original lead SSA, 26
displayed increased anticancer activity by 6-7-fold in colon and prostate cancer cells and by 27-fold in breast cancer
cells. Although 26  possesses higher lipophilicity (logD 5.13) than desirable, this compound may serve as a starting
scaffold for further design and optimization efforts. Based on the presented results, several compounds are candidates
for mechanistic studies and in vivo evaluations, and these advanced assays will be part of separate studies. This new
library  of  sulindac/SSA  analogs  with  the  associated  cancer  cell  line  growth  inhibition  data  will  hopefully  provide
interested researchers with a basis for advancing s or related active analogs into advanced in vitro and in vivo studies
that will expand our knowledge of the anticancer properties and targets of the NSAIDs.
SUPPLEMENTARY MATERIALS
Appendix A
Screening  against  HT29  colorectal  carcinoma,  PC3  prostate  and  MDA-MB-231  breast  cancer  cell  lines  are
described. Results of additional cancer cell line screens and cytotoxicity data is summarized in Table S1. Computed
physicochemical properties of compounds 7-33 are listed in Table S2.
Appendix B
General experimental methods, synthetic procedures and analytical data are provided.
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